P-MAPA

**P-MAPA** is a complex, high-molecular weight biopolymer derived via fermentation from *Aspergillus oryzae*, characterized as protein magnesium ammonium phospholinoleate-palmitoleate-anhydride polymer aggregated (approximate molecular weight ~320 kDa). It acts as an **immunomodulatory agent**, primarily investigated for bladder cancer and other malignancies. Mechanistically, P-MAPA is distinct from BCG: it activates pattern recognition receptors, specifically **Toll-Like Receptor 2 (TLR-2)** and **Toll-Like Receptor 4 (TLR-4)**, leading to a cascade of immune-mediated effects including strong activation of the **interferon signaling pathway**, restoration of p53 protein levels, inhibition of angiogenesis via suppression of **vascular endothelial growth factor (VEGF)**, reduction of androgen receptor expression, and increase of estrogen receptor expression. Preclinical and some clinical data suggest it is superior to BCG in certain bladder cancer settings, with a strongly favorable safety profile.

Brand names

P-MAPA

Other names

protein magnesium ammonium phospholinoleate-palmitoleate-anhydride polymer aggregated